BACKGROUND: CX3CL1 is a member of the chemokine family, and its receptor, CX3CR1, is expressed in pancreatic ductal adenocarcinoma. However, it is unclear whether there is a correlation between the expression of CX3CL1/CX3CR1 axis and the prognosis of patients with pancreatic ductal adenocarcinoma. METHODS: Tissue microarray and immunohistochemistry were used to study the expression of CX3CL1 and CX3CR1 in 105 specimens of pancreatic ductal adenocarcinoma. We analyzed a relationship between patients' clinicopathological parameters and overall survival to the expression level of the CX3CL1/CX3CR1 axis using standard statistical analysis. RESULTS: The expression of CX3CL1 and CX3CR1 (77.1 and 66.7 %, respectively) was clearly increased in areas of malignancy compared with peritumoral areas. We did not find any correlation between CX3CL1 and CX3CR1 expression with clinical or pathological data. Patients' overall survival was clearly worse with the combined high expression of CX3CL1 and CX3CR1. Patients with a high CX3CL1 expression tumor had a significantly shorter overall survival. High CX3CR1 expression was an independent negative prognosis factor. CONCLUSION: We propose that the expression level of CX3CL1/CX3CR1 axis could provide clinical prognostic value, and the next steps should be to further investigate the mechanism by which CX3CL1 and its receptor impact survival in pancreatic ductal adenocarcinoma.
BACKGROUND:CX3CL1 is a member of the chemokine family, and its receptor, CX3CR1, is expressed in pancreatic ductal adenocarcinoma. However, it is unclear whether there is a correlation between the expression of CX3CL1/CX3CR1 axis and the prognosis of patients with pancreatic ductal adenocarcinoma. METHODS: Tissue microarray and immunohistochemistry were used to study the expression of CX3CL1 and CX3CR1 in 105 specimens of pancreatic ductal adenocarcinoma. We analyzed a relationship between patients' clinicopathological parameters and overall survival to the expression level of the CX3CL1/CX3CR1 axis using standard statistical analysis. RESULTS: The expression of CX3CL1 and CX3CR1 (77.1 and 66.7 %, respectively) was clearly increased in areas of malignancy compared with peritumoral areas. We did not find any correlation between CX3CL1 and CX3CR1 expression with clinical or pathological data. Patients' overall survival was clearly worse with the combined high expression of CX3CL1 and CX3CR1. Patients with a high CX3CL1 expression tumor had a significantly shorter overall survival. High CX3CR1 expression was an independent negative prognosis factor. CONCLUSION: We propose that the expression level of CX3CL1/CX3CR1 axis could provide clinical prognostic value, and the next steps should be to further investigate the mechanism by which CX3CL1 and its receptor impact survival in pancreatic ductal adenocarcinoma.
Authors: F Andre; N Cabioglu; H Assi; J C Sabourin; S Delaloge; A Sahin; K Broglio; J P Spano; C Combadiere; C Bucana; J C Soria; M Cristofanilli Journal: Ann Oncol Date: 2006-04-20 Impact factor: 32.976
Authors: Y Pan; C Lloyd; H Zhou; S Dolich; J Deeds; J A Gonzalo; J Vath; M Gosselin; J Ma; B Dussault; E Woolf; G Alperin; J Culpepper; J C Gutierrez-Ramos; D Gearing Journal: Nature Date: 1997-06-05 Impact factor: 49.962
Authors: T Imai; K Hieshima; C Haskell; M Baba; M Nagira; M Nishimura; M Kakizaki; S Takagi; H Nomiyama; T J Schall; O Yoshie Journal: Cell Date: 1997-11-14 Impact factor: 41.582
Authors: Patricia Harnden; Michael D Shelley; Hayley Clements; Bernadette Coles; R Sandy Tyndale-Biscoe; Brian Naylor; Malcolm D Mason Journal: Cancer Date: 2007-01-01 Impact factor: 6.860
Authors: Federica Marchesi; Lorenzo Piemonti; Giuseppe Fedele; Annarita Destro; Massimo Roncalli; Luca Albarello; Claudio Doglioni; Achille Anselmo; Andrea Doni; Paolo Bianchi; Luigi Laghi; Alberto Malesci; Luigi Cervo; Marialuisa Malosio; Michele Reni; Alessandro Zerbi; Valerio Di Carlo; Alberto Mantovani; Paola Allavena Journal: Cancer Res Date: 2008-11-01 Impact factor: 12.701
Authors: Wilson Petrushnko; Justin S Gundara; Philip R De Reuver; Greg O'Grady; Jaswinder S Samra; Anubhav Mittal Journal: HPB (Oxford) Date: 2016-07-14 Impact factor: 3.647
Authors: Gemma Ferrer-Mayorga; Silvia Alvarez-Díaz; Noelia Valle; Javier De Las Rivas; Marta Mendes; Rodrigo Barderas; Francesc Canals; Olga Tapia; J Ignacio Casal; Miguel Lafarga; Alberto Muñoz Journal: J Biol Chem Date: 2015-09-13 Impact factor: 5.157
Authors: Lauren E Colbert; Sarah B Fisher; Claire W Hardy; William A Hall; Burcu Saka; Joseph W Shelton; Aleksandra V Petrova; Matthew D Warren; Brooke G Pantazides; Khanjan Gandhi; Jeanne Kowalski; David A Kooby; Bassel F El-Rayes; Charles A Staley; N Volkan Adsay; Walter J Curran; Jerome C Landry; Shishir K Maithel; David S Yu Journal: Cancer Date: 2013-05-29 Impact factor: 6.860
Authors: G Celesti; G Di Caro; P Bianchi; F Grizzi; F Marchesi; G Basso; D Rahal; G Delconte; M Catalano; P Cappello; M Roncalli; A Zerbi; M Montorsi; F Novelli; A Mantovani; P Allavena; A Malesci; L Laghi Journal: Br J Cancer Date: 2013-10-01 Impact factor: 7.640